Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 45

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 45
---
 ​ | ​ | Position with the CombinedCompany                     | ​ | ​ | Current Position at Tvardi                            | ​ |
| Imran Alibhai, Ph.D.        | ​ | ​ | Chief Executive Officer and Director                  | ​ | ​ | Chief Executive Officer and Director                  | ​ |
| Dan Conn, J.D., M.B.A.      | ​ | ​ | Chief Financial Officer                               | ​ | ​ | Chief Financial Officer                               | ​ |
| John Kauh, M.D.             | ​ | ​ | Chief Medical Officer                                 | ​ | ​ | Chief Medical Officer                                 | ​ |
| Jeffrey Larson, Ph.D., DABT | ​ | ​ | Senior Vice President, Research & Development         | ​ | ​ | Senior Vice President, Research & Development         | ​ |
| Yixin “Joseph” Chen, Ph.D.  | ​ | ​ | Vice President, Chemistry, Manufacturing and Controls | ​ | ​ | Vice President, Chemistry, Manufacturing and Controls | ​ |

Directors of the Combined Company Following the Merger At the Effective Time, the combined company is expected to initially have a seven-member board of directors, comprised of five members designated by Tvardi (Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk and Imran Alibhai), one member to be designated by Cara prior to Closing and one vacancy, to be designated by Tvardi if prior to the closing of the Merger or by the combined company if following the consummation of the Merger, until their respective successors are duly elected or appointed and qualified or their earlier death, resignation or removal. If the one remaining director is not identified prior to the Effective Time, the Combined Company Board anticipates reducing the size of the Combined Company Board to six directors. The aforementioned Combined Company Board will have an audit committee, a compensation committee and a nominating and corporate governance committee, in accordance with the Nasdaq rules. All of Cara’s current directors, other than the member to be designated by Cara prior to Closing, are expected to resign from their positions as directors of Cara, effective as of the Effective Time. Interests of Certain Directors and Executive Officers of Cara and Tvardi in the Merger In considering the recommendation of the Cara Board with respect to the issuance of Cara common stock pursuant to the Merger Agreement and the other matters to be acted upon by Cara’s stockholders at the Cara special meeting, Cara’s stockholders should be aware that certain members of the Cara Board